SIRT3 and liver cancer: Activators of SIRT3, such as Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN), enhance SIRT3 activity, decrease lactylation levels, and inhibit liver cancer progression while sensitizing chemotherapy (Mukherjee et al., 2021; Zhao et al., 2022b).